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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this systematic review is to evaluate the effectiveness of aspirin and other NSAIDs in the primary and secondary
prevention of dementia.
B A C K G R O U N D
Dementia is a term used to describe a variety of illnesses which,
although diverse in nature, share common clinical manifestations.
Typified by pervasive impairment of mental functioning, progres-
sive memory loss, language difficulties, confusion and disorienta-
tion, dementia leads to a decline in the skills required to carry out
everyday living activities (Coteilli 2012). Symptoms of demen-
tia also affect behaviour and mood (Cohen-Mansfield 2000; Hoe
2005;Hoe 2006;Hoe 2007;Hoe 2009). As the disease progresses,
the increasing severity of symptoms has a devastating effect on the
quality of life of the person with dementia and their caregivers
(World Health Organization 2012). Dementia is a terminal dis-
ease that is largely, but not exclusively, a disorder of old age (O
Shea 2011). As the disease progresses, the associated increase in
frequency and severity of symptoms has a devastating effect on the
quality of life of the person with dementia and his or her caregivers
(World Health Organization 2012).
While dementia primarily affects older people, there is increasing
awareness of cases that start before the age of 65 years. After 65
years, the prevalence of dementia doubles with every five-year in-
crease in age. Current estimates suggest that there are 35.6 mil-
lion people living with dementia worldwide, and this is forecast
to double by 2030 and more than triple by 2050. Almost two-
thirds of the dementia population reside in low and middle in-
come countries and this trend is expected to increase. Dementia
is an expensive condition, costing an estimated USD 604 billion
worldwide in 2010. Low and middle income countries, despite
experiencing higher prevalence rates of dementia, account for only
11% of the total worldwide costs; 89% of costs are attributed to
high income countries. These discrepancies are accounted for by
the differences in costs per person across low, middle and high
income countries, estimated at USD 868, USD 6827 and USD
32,865 respectively. The cost of informal care constitutes the bulk
of costs in the low and middle income countries, while the direct
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costs of social care have a much greater role in the high income
countries due to the costs of long term residential and nursing
home care in these countries (Wimo 2010). Given the seriousness
of the impact of dementia on all associated with the illness and
its increasing prevalence and burden of cost, the World Health
Organization 2012 has declared dementia a national and world
health priority. There is global interest in research into ways of
preventing or delaying the onset of dementia.
Description of the condition
Dementia: main subtypes and pathophysiology
Alzheimer’s disease
Alzheimer’s disease (AD)was first described byDrAlois Alzheimer,
a German psychiatrist and neuropathologist, in 1906. It is now
considered to be the most common cause of dementia, account-
ing for 60% to 80% of all cases. A dementia due to AD affects
approximately 15 million individuals worldwide (World Health
Organization 2012). It has a prevalence of approximately 1%
among 60 to 64 year olds, increasing to 40% in people aged 85
years and older (Brookmeyer 1998). AD is a neurodegenerative
disorder. It is characterised pathologically by neuritic plaques and
neurofibrillary tangles, and clinically by gradually progressive cog-
nitive decline, impairments in activities of daily living, and be-
havioural and psychological symptoms (Gorelick 2010). As yet,
the precise mechanisms underlying the pathogenesis of AD are
not understood fully, but over 25 years ago a hypothesis was first
posited that inflammatory processes are an integral part of the de-
generation process (Rogers 1988; McGeer 1995; McGeer 1997).
Although dementia due to AD typically occurs in later life, there
is an extended preclinical stage that is characterised by progressive
neuropathological changes. Risk factors for AD are multiple but
two of the greatest risk factors are old age and genetics, specifically
being a carrier of the APOE e4 allele of the gene for apoplipopro-
tein E. Other risk factors include history of mild cognitive impair-
ment (MCI), female gender, cardiovascular disease, obesity, dia-
betes mellitus and low socioeconomic status, quantified as low in-
come and low level of educational attainment (Barnes 2011; Yaffe
2013).
Vascular dementia
Vascular dementia (VaD) is the second most common type of de-
mentia. It is caused by cerebrovascular disease that directly or indi-
rectly damages the brain structures associated with cognitive func-
tioning (Roh 2014). Two factors are necessary for a diagnosis of
VaD. These are (a) a cognitive disorder evident on neuropsycho-
logical testing, and (b) a history of clinical stroke or cerebrovas-
cular disease detected by neuroimaging which is plausibly linked
to the cognitive disorder. VaD can be classified into 1. multi-in-
farct dementia, 2. strategic infarct dementia, 3. haemorrhagic de-
mentia, 4. subcortical ischaemic vascular dementia (SIVD), and 5.
other forms of VaD. The first three types of VaDmay present with
sudden onset or sudden exacerbations due to acute cerebrovas-
cular events. Their specific symptoms depend on the cortical or
subcortical regions affected. The classic clinical picture is of step-
wise progression, where periods of stability are interrupted by pe-
riods of rapid decline, fluctuation of symptoms and the presence
of focal neurological signs (Pendlebury 2009). In contrast, SIVD
is associated with an insidious onset and gradual cognitive decline,
mimicking the course of AD (Chui 2007. It is caused by steno-
sis and occlusion of small vessels, which results in white matter
ischaemia and multiple lacunar infarcts in subcortical structures.
Finally, other forms of VaD have heterogeneous causes (for exam-
ple vasculitis, cerebral amyloid angiopathy, and hereditary diseases
such as cerebral autosomal dominant arteriopathywith subcortical
infarcts and leukoencephalopathy (CADASIL) (Seo 2007; Park
2013; Patel 2013). Risk factors for VaD are also multifactorial and
include advancing age, male gender, history of cardiovascular dis-
ease, diabetes, obesity and smoking (McCullagh 2001).
Mixed dementia
It has become increasingly apparent that mixed pathologies of de-
mentia subtypes exist, particularly in older patients. Post-mortem
results of 1050 people with dementia showed that 86% revealed
Alzheimer-related pathology but only 42.8% exhibited ’pure’ AD,
with additional cerebrovascular lesions in 22.6% and Lewy body
pathology in 10.8% (Jellinger 2006).
Description of the intervention
Aspirin and other non-steroidal anti-inflammatory drugs
Aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) are indicated for the alleviation of pain, inflammation
and fever. Due to its anti-aggregation effects on platelets, aspirin
is also indicated for the treatment and prevention of cardiovas-
cular disease. Depending on the drug type, dose and duration of
treatment, NSAIDs are associated with a variety of adverse effects
including gastrointestinal ulcers, serious cardiovascular events, hy-
pertension, acute renal failure and worsening of pre-existing heart
failure.
Aspirin (a derivative of salicylate) was the original NSAID. It
was introduced onto the market in the late 19th century. Further
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NSAIDs such as indomethacin and ibuprofen began to appear in
the 1960s (Conaghan 2012). However, it was not until the early
1970s that the mechanism of action of aspirin (and by extension
other NSAIDs) was elucidated by John Vane (Vane 1971). His
work identified it as an inhibitor of the enzyme cyclo-oxygenase
(COX). COX is responsible for the first stage in the production of
prostaglandins, local hormones that have a range of physiological
functions. Originally it was thought that all prostaglandin synthe-
sis was initiated by a single form of COX, but now at least two
isoforms of COX are known to exist, termed COX-1 and COX-2.
COX-1 is present in small amounts inmost human tissues and acts
as a housekeeping enzyme, involved in the regulation of normal
physiological processes such as the maintenance of gastric mucosal
integrity, kidney function and platelet aggregation. Conversely,
COX-2 is undetectable in most tissues under normal physiolog-
ical circumstances and is selectively up-regulated after exposure
to inflammatory mediators or trauma, contributing to subsequent
inflammatory responses and pain.
NSAIDs may be classified according to their selectivity for COX-
1 or COX-2, or both (Vane 1998). Early NSAIDs, including as-
pirin, are non-selective COX inhibitors. It was hypothesised that
the therapeutic effects (that is analgesic, antipyretic, and anti-in-
flammatory benefits) of all NSAIDs, including aspirin, were due
to inhibition of COX-2 and that unwanted side effects were due
to inhibition of COX-1 (Vane 1998). Hence it was thought that if
selective COX-2 inhibitors could be developed, such compounds
should have a similar efficacy to non-selective NSAIDs but with an
improved safety profile as they would allow the continued produc-
tion of prostaglandins in locations such as the gastrointestinal tract
and thus limit adverse effects such as mucosal ulceration (Hawkey
1999). Several COX-2 selective inhibitors were subsequently de-
veloped and marketed, including meloxicam, nimesulide and the
even more highly selective COX-2 inhibitors known collectively
as the coxibs. However, some of these highly selective compounds
(namely rofecoxib and valdecoxib) have subsequently been with-
drawn from the market for safety reasons, due to increased car-
diovascular risk. Such compounds are also not devoid of gastroin-
testinal problems, although the risk is less than with non-selective
NSAIDs (Patricio 2013).
Besides their well-defined effects on the COX isoforms, certain
NSAIDs have been proposed to have an effect on the formation of
amyloid-beta (Aβ), themajor component of the plaques associated
with AD. The synthesis of Aβ requires the enzyme γ -secretase.
Inhibition of this enzyme is an actively pursued disease-modifying
target for AD (Ozudogru 2012), particularly if it can be achieved
by not interfering with the processing of other substrates for the
enzyme thereby conferring a selectivity of action (Crump 2013).
Drugs with such properties are known as g-secretase modulators
(GSMs). However, the NSAIDs that possess this GSM property
(namely ibuprofen, fluribiprofen, indomethacin and sulindac) are
weak in vitro inhibitors of the enzyme and have low brain pene-
trability (Crump 2013) thus putting into question the relevance
of this property in a clinical setting.
How the intervention might work
In recent years, a well-defined neuroinflammatory response has
been identified in Alzheimer’s disease with considerable inflam-
mation observed around the plaques and tangles that represent the
core histological features of the disease.COXenzymes and their in-
fluence on prostaglandin pathways have thus come to attention as
a possible therapeutic target (McGeer 2000; Cudaback 2014). The
anti-inflammatory properties of aspirin and other NSAIDs may
interrupt or prevent inflammatory processes which are important
in pathogenesis, thus preventing the onset of AD (Etminan 2003).
Moreover, the effect on the production of Aβ represents another
possible mechanism of reducing one of the principal pathological
hallmarks of AD, but with the caveats mentioned previously. As-
pirin and other NSAIDs may prevent VaD via their anti-inflam-
matory and anti-platelet effects (Devine 2003).
Why it is important to do this review
A considerable body of research has accumulated that investigates
whether aspirin and other NSAIDs may have a role in the preven-
tion or management of dementia due to AD and VaD. Evidence to
support such use of NSAIDs stems largely from epidemiological
studies. Epidemiolgical studies report a lower prevalence of AD
in patients who have regularly taken NSAIDs for the treatment
of rheumatological disorders, suggesting that NSAIDs may have
a protective effect against AD (McGeer 1996; Stewart 1997; In’d
Veld 2001). Reviews of epidemiological studies also suggest that
the protective effects may be influenced by the type and duration
of NSAID use. Long term use (defined as greater than 24 months)
was associated with greater risk reduction than short term use (de-
fined as less than 1 month) or intermediate term use (defined as 1
to 24 months) (Etminan 2003; Szekely 2004).
The effectiveness of aspirin and other NSAIDs as treatments for
patients with dementia due to AD and VaD has been evaluated in
Cochrane systematic reviews (Rands 2000; Jaturapatporn 2012).
The promising epidemiological evidence has not been reproduced
in prospective randomised clinical trials, whose results have been
largely disappointing. As yet, there has been no Cochrane system-
atic review on the effectiveness of aspirin and other NSAIDs in the
prevention of dementia. As dementia, particularly AD or VaD, is
such a major health concern worldwide, any intervention that de-
lays or prevents the onset of dementia would have a major public
health impact. We therefore considered it important to assess in
a systematic review the strength of the evidence on the safety and
efficacy of these drugs for the primary and secondary prevention
of dementia.
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O B J E C T I V E S
The objective of this systematic review is to evaluate the effective-
ness of aspirin and other NSAIDs in the primary and secondary
prevention of dementia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include only randomised or quasi-randomised, double-
blind trials in which aspirin and other NSAIDs were administered
for the primary or secondary prevention of dementia. All doses
and durations of treatment with aspirin and other NSAIDs will
be considered.
Types of participants
Participants will be adults living in the community setting with-
out a prior diagnosis of dementia. Participants may be identified
as cognitively healthy or with mild cognitive impairment (MCI).
A variety of definitions of MCI will be accepted but participants
with MCI will only be considered for inclusion if they meet the
following criteria: (a) there is objective evidence of cognitive de-
cline greater than expected for age, and (b) no significant impair-
ment in activities of daily living.
Types of interventions
We will include the following comparisons:
1. aspirin at any dose with placebo;
2. other NSAIDs at any dose with placebo.
Types of outcome measures
Primary outcomes
• Incidence of dementia, diagnosed according to standard
diagnostic criteria or those appropriate at the time the study was
undertaken
• Adverse events, e.g. cardiovascular, gastrointestinal or renal
events
• Mortality
Secondary outcomes
• Cognitive decline from baseline
• Activities of daily living (ADL)
• Health-related quality of life
Search methods for identification of studies
Electronic searches
We will search ALOIS (www.medicine.ox.ac.uk/alois), the
Cochrane Dementia and Cognitive Improvement Group Special-
ized Register. The search terms we will use are: aspirin OR “cy-
clooxygenase 2 inhibitor” OR aceclofenac OR acemetacin OR
celecoxib OR dexibruprofen OR dexketoprofen OR diclofenac
sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib
OR fenbufen OR fenoprofen OR flurbiprofen OR ibuprofen OR
indometacin OR indomethacin OR ketoprofen OR lumiracoxib
OR mefenamic OR meloxicam OR nabumetone OR naproxen
ORnimesulideOR “anti-inflammatory”ORpiroxicamOR sulin-
dac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR
NSAIDS OR NSAID.
ALOIS is maintained by the Trials Search Co-ordinator for the
Cochrane Dementia Group and contains studies in the areas of
dementia prevention, dementia treatment and cognitive enhance-
ment in healthy people. The studies are identified from the fol-
lowing.
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS.
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the World Health Organization
(WHO) International Clinical Trials Registry Platform portal
(which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical
Trials Register; the German Clinical Trials Register; the Iranian
Registry of Clinical Trials; and the Netherlands National Trials
Register, plus others).
3. Quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL).
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for by ALOIS see About
ALOIS on the ALOIS website.
Additional separate searches will be run in many of the above
sources to ensure that the most up-to-date results are retrieved.
The search strategy that will be used for the retrieval of reports of
trials from MEDLINE (via the OvidSP platform) can be seen in
Appendix 1.
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Searching other resources
We will review citations of reference lists of included studies iden-
tified through the search strategy, described above, for additional
studies and assess their suitability for inclusion in the review.
We will not apply any language restrictions.
Data collection and analysis
The methods that will be undertaken in this review were designed
in accordance with recommendations described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
Two review authors (FJ and DD) will independently screen all
titles and abstracts identified from searches to identify those which
might meet the inclusion criteria. We will retrieve in full text any
papers identified as potentially relevant by at least one author. The
same review authors will independently screen full text articles
for inclusion or exclusion. Any disagreement will be resolved by
discussion or, if necessary, we will consult a third review author
(KM or PP). All papers excluded from the review at the full text
stage will be listed as excluded studies, with reasons provided in
the ‘Characteristics of excluded studies’ table.
Data extraction and management
We will design a data extraction form. Two review authors (FJ and
KM) will independently extract data from eligible studies using
this form. Any discrepancies will be resolved through discussion
or, if necessary, we will consult with a third review author (BMcG
or PP). All extracted data will be entered into RevMan (RevMan
2012) by one review author (FJ), and checked for accuracy against
the data extraction sheets by a second review author (KM)working
independently. When information regarding any of the included
studies is unclear, we will endeavour to contact the authors of the
original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors (FJ and DD) will independently assess risk
of bias for each of the included studies using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will resolve any disagreements by discussion
or, if necessary, we will involve another review author.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the risk of bias for sequence generation as:
• low risk (any truly random process, e.g. random number
table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of
birth; hospital or clinic record number);
• unclear risk.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the risk of bias for allocation concealment as:
• low risk (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk (e.g. open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);
• unclear risk.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded.
We will assess the risk of bias for blinding of participants and
personnel as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received.
We will assess the risk of bias for blinding of outcome assessment
as:
• low risk;
• high risk;
• unclear risk.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome,
the completeness of data including attrition and exclusions from
the analysis. We will state whether attrition and exclusions were
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reported, the numbers included in the analysis at each stage (com-
pared with the total number of randomised participants), reasons
for attrition or exclusionwhere reported, andwhethermissing data
were balanced across groups or were related to outcomes. Where
sufficient information is reported, or can be supplied by the trial
authors, we will re-include missing data in the analyses which we
undertake. We will assess the risk of bias for incomplete outcome
data as:
• low risk (e.g. no missing outcome data; missing outcome
data balanced across groups; < 20% missing data);
• high risk (e.g. frequency of or reasons for missing data that
are imbalanced across groups; > 20% missing data);
• unclear risk.
(5) Selective reporting (checking for reporting bias)
We will investigate the possibility of selective outcome reporting
bias by cross-checking outcomes of interest reported in the meth-
ods section to those reported in the results section of the trial pub-
lications.
We will assess the risk of bias for selective reporting as:
• low risk (where it is clear that all of the study’s pre-specified
outcomes and all expected outcomes of interest to the review
have been reported);
• high risk (where not all the study’s pre-specified outcomes
have been reported; one or more reported primary outcomes were
not pre-specified; outcomes of interest are reported incompletely
and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear risk.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess the risk of other forms of bias as:
• low risk;
• high risk;
• unclear risk.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we will assess the likely magni-
tude and direction of the bias and whether we consider it is likely
to impact on the findings. We will explore the impact of the level
of bias through undertaking sensitivity analyses (see ’Sensitivity
analysis’) and wewill assess the overall risk of bias for each included
study as:
• low risk;
• high risk;
• unclear risk.
Measures of treatment effect
Dichotomous data
For dichotomous data such as dementia or no dementia, we will
present results as summary risk ratios with 95% confidence inter-
vals (95% CI).
Continuous data
For continuous data, we will use the mean difference with 95%
CI if outcomes are measured with the same scale in all trials.
We will use the standardised mean difference with 95% CI to
combine outcomes from trials that measure the same outcome but
use different scales (Higgins 2011).
Time-to-event data
Survival analysis will be considered for time-to-event data and the
intervention effect expressed as a hazard ratio. Methods used to
analyse time-to-event outcomes will be guided by those described
by Tierney et al (Tierney 2007 and detailed in Chapter 7, section
7.7.6. of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011).
For all outcomes we will assess the quality of the evidence con-
tributing to the estimate of the treatment effect using GRADE
ratings. For the primary outcomes and the secondary outcomes of
cognition and ADL, we will present these assessments in a sum-
mary of findings table.
Unit of analysis issues
Studies with multiple treatment groups
If a study involvesmore than two treatment groups, then any treat-
ment groups not relevant to the review objectives will be excluded.
If more than two groups are relevant to a single meta-analysis, then
groups will be combined to form single experimental and control
groups.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels ofmissing data (we
judge this a priori to be greater than 20% for a primary outcome)
in the overall assessment of treatment effect by using sensitivity
analysis.
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For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis. If intention-to-treat data are not
available in the publications, ’on-treatment’ or the data for those
who complete the trial shall be sought and indicated as such.
Assessment of heterogeneity
Where studies are considered similar enough (based on consider-
ation of populations and interventions) to allow pooling of data
using meta-analysis, we will assess the degree of heterogeneity by
visual inspection of forest plots and by examining the Chi² test
for heterogeneity. We will assess statistical heterogeneity in each
meta-analysis using the T², I² and Chi² statistics. We will regard
statistical heterogeneity as substantial if an I² statistic is greater
than 30% and either the T² is greater than zero or there is a low P
value (less than 0.10) in the Chi² test for heterogeneity.
Where we identify substantial clinical, methodological or statisti-
cal heterogeneity across included studies, we will consider if it is
appropriate to report a pooled effect result from the meta-analysis
or use a narrative approach to synthesise data. In this event, we
will attempt to explore possible reasons for the heterogeneity by
grouping studies that have similar populations and interventions.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it. We acknowledge that publication bias
may not be the only cause of funnel plot asymmetry. If a small
study effect is apparent, we will explore other potential reasons,
for example diversity in methodological quality, bias and genuine
heterogeneity in the intervention effect. If justified, we will inves-
tigate other possible causes by undertaking a sensitivity analysis
(Sterne 2011).
Data synthesis
Wewill conduct separate analyses for studies of cognitively healthy
participants and studies of participants with MCI.
We will carry out statistical analysis using the Review Manager
software (RevMan 2012). We will use fixed-effect model meta-
analysis for combining data where it is reasonable to assume that
studies are estimating the same underlying treatment effect, that
is where participants, interventions and methods are judged suf-
ficiently similar. If there is clinical heterogeneity sufficient to ex-
pect that the underlying treatment effects differ between trials, or
if substantial statistical heterogeneity is detected, we will use ran-
dom-effects model meta-analysis to produce an overall summary
if an average treatment effect across trials is considered clinically
meaningful. The random-effects model summary will be treated
as the average range of possible treatment effects and we will dis-
cuss the clinical implications of treatment effects differing between
trials. If the average treatment effect is not clinically meaningful,
we will not combine trials.
If we use random-effects model analyses, the results will be pre-
sented as the average treatment effect with 95% CI and with the
estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
Where data are available, wewill conduct an analysis based on rele-
vant and clinically meaningful subgroups such as class of NSAIDs,
that is non-selective COX inhibitors and selective COX-2 in-
hibitors; dose of NSAIDs, low versus high doses of NSAIDs; and
duration of use, short term use (less than one month of cumulative
use), intermediate term use (one month or more but less than 24
months of cumulative use); and long term use (greater than two
years cumulative use).
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2012). We will report the results of
subgroup analyses quoting the Chi2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
We will perform sensitivity analyses based on trial quality by re-
peating our analysis for only those trials judged of ’high quality’.
For the purposes of this review, high quality trials will be defined
as trials with low risk of bias due to allocation concealment and
low risk of bias due to incomplete outcome data.
These sensitivity analyses will also assist in investigating substan-
tial statistical heterogeneity if present (see Assessment of hetero-
geneity).
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Aspirin/
2. aspirin.ti,ab.
3. “acetylsalicylic acid”.ti,ab.
4. “cyclooxygenase 2 inhibitor”.ti,ab.
5. aceclofenac.ti,ab.
6. acemetacin.ti,ab.
7. celecoxib.ti,ab.
8. dexibruprofen.ti,ab.
9. dexketoprofen.ti,ab.
10. diclofenac sodium.ti,ab.
11. diflunisal.ti,ab.
12. diflusinal.ti,ab.
13. etodolac.ti,ab.
14. etoricoxib.ti,ab.
15. fenbufen.ti,ab.
16. fenoprofen.ti,ab.
17. flurbiprofen.ti,ab.
18. ibuprofen.ti,ab.
19. indometacin.ti,ab.
20. indomethacin.ti,ab.
21. ketoprofen.ti,ab.
22. lumiracoxib.ti,ab.
23. mefenamic.ti,ab.
24. meloxicam.ti,ab.
25. nabumetone.ti,ab.
26. naproxen.ti,ab.
27. nimesulide.ti,ab.
28. anti-inflammatory.ti,ab.
29. piroxicam.ti,ab.
30. sulindac.ti,ab.
31. tenoxicam.ti,ab.
32. tiaprofenic acid.ti,ab.
33. triamcinolone.ti,ab.
34. NSAIDS.ti,ab.
35. NSAIDS.ti,ab.
36. *Anti-Inflammatory Agents, Non-Steroidal/
37. Cyclooxygenase Inhibitors/
38. Triamcinolone/
39. Sulindac/
40. Piroxicam/
41. Sulfonamides/
42. Naproxen/
43. Mefenamic Acid/
44. Diclofenac/
45. Cyclooxygenase 2 Inhibitors/
46. Ketoprofen/
47. Indomethacin/
48. Indomethacin/
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49. Ibuprofen/
50. Flurbiprofen/
51. Fenoprofen/
52. Diclofenac/
53. or/1-52
54. dement*.ti,ab.
55. exp Dementia/
56. (cognition or cognitive).ti,ab.
57. Cognition/
58. Cognition Disorders/
59. MCI.ti,ab.
60. ACMI.ti,ab.
61. ARCD.ti,ab.
62. SMC.ti,ab.
63. CIND.ti,ab.
64. BSF.ti,ab.
65. AAMI.ti,ab.
66. MD.ti,ab.
67. LCD.ti,ab.
68. QD.ti,ab.
69. AACD.ti,ab.
70. MNCD.ti,ab.
71. MCD.ti,ab.
72. (“N-MCI” or “A-MCI” or “M-MCI”).ti,ab.
73. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or deteriorat* or degenerat* or complain* or disturb*
or disorder*)).ti,ab.
74. “preclinical AD”.ti,ab.
75. “pre-clinical AD”.ti,ab.
76. (aMCI or MCIa).ti,ab.
77. (“CDR 0.5” or “clinical dementia rating scale 0.5”).ti,ab.
78. (“GDS 3” or “stage 3 GDS”).ti,ab.
79. (“global deterioration scale” and “stage 3”).ti,ab.
80. “Benign senescent forgetfulness”.ti,ab.
81. “mild neurocognit* disorder*”.ti,ab.
82. (prodrom* adj2 (dement* or AD)).ti,ab.
83. (episodic* adj2 memory).ti,ab.
84. Secondary Prevention/ or Primary Prevention/
85. alzheimer*.ti,ab.
86. “healthy elderly”.ti,ab.
87. (cognit* adj3 health*).ti,ab.
88. “older adult*”.ti,ab.
89. Aged/ or Middle Aged/
90. pensioner*.ti,ab.
91. “senior citizen*”.ti,ab.
92. “community dwelling”.ti,ab.
93. or/54-93
94. 53 and 93
95. randomized controlled trial.pt.
96. controlled clinical trial.pt.
97. (Randomized or randomised).ti,ab.
98. (randomly or quasi-random* or quasi-experiment*).ab.
99. placebo*.ab.
100. groups.ab.
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101. or/95-100
102. (animals not (humans and animals)).sh.
103. 101 not 102
104. 94 and 103
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